Selecta Biosciences Current Ratio 2015-2021 | SELB

Selecta Biosciences current ratio from 2015 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Selecta Biosciences Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.17B $0.09B 1.91
2021-03-31 $0.16B $0.09B 1.93
2020-12-31 $0.15B $0.08B 1.86
2020-09-30 $0.17B $0.08B 2.16
2020-06-30 $0.06B $0.02B 2.71
2020-03-31 $0.07B $0.03B 2.48
2019-12-31 $0.10B $0.04B 2.77
2019-09-30 $0.04B $0.03B 1.23
2019-06-30 $0.04B $0.03B 1.39
2019-03-31 $0.06B $0.03B 1.80
2018-12-31 $0.04B $0.04B 1.20
2018-09-30 $0.06B $0.04B 1.61
2018-06-30 $0.07B $0.01B 4.96
2018-03-31 $0.09B $0.01B 7.20
2017-12-31 $0.10B $0.01B 8.99
2017-09-30 $0.11B $0.01B 9.48
2017-06-30 $0.12B $0.02B 5.71
2017-03-31 $0.07B $0.01B 5.37
2016-12-31 $0.09B $0.01B 6.33
2016-09-30 $0.08B $0.01B 10.85
2016-06-30 $0.09B $0.01B 9.96
2016-03-31 $0.00B 0.00
2015-12-31 $0.00B 0.00
2015-09-30 $0.00B 0.00
2015-06-30 $0.00B 0.00
2014-12-31 $0.02B $0.01B 2.07
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.455B $0.017B
Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76